China Actions Against MNCs No Deterrence To Further Drug Investments
This article was originally published in PharmAsia News
Executive Summary
AstraZeneca, Eli Lilly, GlaxoSmithKline, Johnson & Johnson and Sanofi have been caught up in China legal action affecting the drug industry, but that will not deter AZ from investing in the country, CEO Pascal Soriot said.